Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $461000.0.

  • Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) fell 960.78% to $461000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 5382.23%. This contributed to the annual value of $3.4 million for FY2024, which is 2027.5% down from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) is $461000.0, which was down 960.78% from $483000.0 recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Depreciation & Amortization (CF) high stood at $1.3 million for Q4 2023, and its period low was $461000.0 during Q3 2025.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $893000.0 (2023), whereas its average is $829818.2.
  • The largest annual percentage gain for Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) in the last 5 years was 3549.83% (2024), contrasted with its biggest fall of 6066.61% (2024).
  • Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) (Quarter) stood at $1.3 million in 2023, then tumbled by 60.67% to $496000.0 in 2024, then dropped by 7.06% to $461000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $461000.0 for Q3 2025, versus $483000.0 for Q2 2025 and $493000.0 for Q1 2025.